| Document |
Document Title |
|
WO/2021/050992A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
|
|
WO/2021/045153A1 |
Provided is a method for producing gamma-butyrolactone, said method including a reaction step in which a raw material composed of one or both of 2-hydroxytetrahydrofuran and 4-hydroxybutyraldehyde and a catalyst containing copper and an ...
|
|
WO/2021/045927A1 |
A process for preparing 5-(alkoxycarbonyl)furan-2-carboxylic acids (ACFC) by oxidizing various furcates in the presence of a catalyst containing cobalt, manganese, and bromine, and a solvent while simultaneously removing water vapor from...
|
|
WO/2021/042410A1 |
Disclosed are a selective butyrylcholinesterase inhibitor having general formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, and use thereof. By testing the efficacy of treatment of Alzheimer's disea...
|
|
WO/2021/045207A1 |
The present invention relates to a production method for a highly reactive intermediate. The production method includes: preparing an electron-accepting active compound (1); preparing a piezoelectric material (3); and applying mechanical...
|
|
WO/2021/045527A1 |
The present invention pertains to: a diol compound capable of producing a polycarbonate having excellent mechanical properties, weather resistance, hardness, heat resistance, transparency, and impact resistance; a polycarbonate produced ...
|
|
WO/2021/043194A1 |
Provided are a halogenated tetracyclic triterpene derivative as represented by general formula A, a preparation and an application thereof. R 1 is a halogen, R 2 is H, and the halogen is selected from fluorine, chlorine, bromine or iodin...
|
|
WO/2021/036514A1 |
A novel PPAR γ/δ dual agonist as described in general formula (I), a preparation method thereof and an application of a pharmaceutical composition containing a derivative in the preparation of a drug for prevention and/or treatment of ...
|
|
WO/2021/031999A1 |
The present invention belongs to the field of medicine, and specifically relates to a prodrug of mycophenolic acid and a method for preparation thereof. The structural formula thereof is as shown in formula I; in comparison with mycophen...
|
|
WO/2021/030091A1 |
The present disclosure relates to compounds, compositions and supplements that are capable of treating obesity. The disclosure further relates to methods of treating obesity in a subject in need thereof.
|
|
WO/2021/030773A1 |
The present disclosure relates to extracellular vesicles, e.g., exosomes, comprising an NLRP3 antagonist. In some aspects, the NLRP3 antagonist comprises an antisense oligonucleotide (ASO). Also provided herein are methods for producing ...
|
|
WO/2021/028810A1 |
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...
|
|
WO/2021/023765A1 |
Furan, thiophene or y-lactam sesterterpene tetronic acids of formula (I), process for their preparation or for isolation from marine sponges, as well as to pharmaceutical compositions comprising them and their use in pharmacy, in particu...
|
|
WO/2021/023914A1 |
A composition and a method for use in suppressing growth and/or proliferation of cancer cells in vivo and in vitro is provided. The composition includes an alcoholic lignan extract prepared from coniferous species optionally in combinati...
|
|
WO/2021/021909A1 |
Disclosed are compounds and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are oral dosage forms comprising such a compound, salt, or prodrug. Also disclosed are metho...
|
|
WO/2021/021840A1 |
There is provided a compound having Formula (I) In Formula I = Ar1 is a hydrocarbon aryl group, a heteroaryl group, or a substituted derivative thereof; and Q has Formula (Q1), (Q2), or (Q3) The variables are described in detail herein.
|
|
WO/2021/020429A1 |
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.
|
|
WO/2021/019942A1 |
Provided is a monomer that imparts higher heat resistance to a resin while improving solubility in an organic solvent, hydrolyzability, and solubility in water after hydrolysis. This resin for photoresist contains a polymerization unit r...
|
|
WO/2021/018270A1 |
Disclosed are a host compound applied to the field of organic electroluminescence, and an organic electroluminescent device using same. The molecular structural formula of the organic compound is LA-LB, wherein LA has a structure represe...
|
|
WO/2021/018085A1 |
The present invention relates to the field of pharmaceutical synthesis, and in particular to a preparation method for a hexahydrofurofuranol derivative, and an intermediate of the derivative and a preparation method therefor. The prepara...
|
|
WO/2021/012014A1 |
The present invention relates to methods for preparing a variety of difluorohaloallylamine derivatives. The present invention also relates to novel difluorohaloallylamine derivatives that are capable of inhibiting certain amine oxidase e...
|
|
WO/2021/012721A1 |
Disclosed in the present invention are a naphthalenesulfonamide compound, a preparation method, and an application. The naphthalenesulfonamide compound provided by the present invention can interfere with Keap1-Nrf2 binding and activate ...
|
|
WO/2021/016220A2 |
A method is provided of preparing a compound of formula II: where: R1 and R2 are independently selected from -CH2OR', -CHO, -COOR' and -H, provided that R1 and R2 are not both -H; and R' is selected from -H and C1-6 hydrocarbyl groups, f...
|
|
WO/2021/015555A1 |
The present invention provides: a novel compound which can improve the luminous efficiency, stability, and service life of an element; an organic electric element using same; and an electronic device comprising the organic electric element.
|
|
WO/2021/013155A1 |
Disclosed are a new glycosyl donor, a preparation method therefor, and an application thereof. Specifically, a glycosyl donor represented by formula (I), a preparation method therefor, and a use of the glycosyl donor represented by formu...
|
|
WO/2021/009026A1 |
Compounds of formula (I): (Formula (I)) Formula (I) encompasses e.g. tetraline, chromane, isochromane, 6,7,8,9-tetrahydrobenzo[7]annulene, 1H-isobenzofurane and indane derivatives. The compounds of formula (I) are useful as a pesticides,...
|
|
WO/2021/009566A1 |
Described herein are N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl) carbamoyl)-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds of formula (I) wherein R1 is formulae (II), (III), (IV), (V), (VI), (VII), (VIII) or (...
|
|
WO/2021/011722A1 |
This disclosure relates to compounds having pesticidal utility against pests in phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such compounds and intermediates used in such processes, compositions containing such compo...
|
|
WO/2021/009568A1 |
Provided herein are benzenesulfonamide derivatives having Formula (III), pharmaceutical compositions comprising said compounds, and method for using said compounds for disrupting proteins/polypeptides, protein/polypeptide function, and f...
|
|
WO/2021/007663A1 |
This disclosure relates to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor ...
|
|
WO/2021/009567A1 |
Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2021/007171A1 |
The invention relates to diols derived from 5-hydroxymethyl furfural, diformyl furan, or derivatives thereof. The invention further relates to diglycidyl ethers derived from the diols of the invention, curable coating compositions contai...
|
|
WO/2021/004531A1 |
Provided is a crystalline form of CXCR2 antagonist, application thereof in the preparation of a drug for treating CXCR2-related diseases.
|
|
WO/2021/006817A1 |
The invention concerns a novel cardiac therapeutic effective against atrial fibrillation (AF); a pharmaceutical composition comprising same; the use of same to treat cardiac disease; and a method of treating cardiac disease involving the...
|
|
WO/2021/000041A1 |
The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) Wherein R1 includes an amino group. These compounds are particularly useful in the formulation and in vivo and ex vivo delivery ...
|
|
WO/2020/258412A1 |
The present invention relates to a method for preparing dimethyl furan-2,5-dicarboxylate by oxidizing and esterifying 5-hydroxymethyl furfural, comprising: using air and/or oxygen as an oxidant and using methanol as a solvent and a react...
|
|
WO/2020/259471A1 |
Provided herein are oseltamivir analogs useful for the treatment and prevention of viral infections, pharmaceutical compositions comprising the same and methods preparation and use thereof.
|
|
WO/2020/258689A1 |
Disclosed is a method for preparing an aviation fuel intermediate from cellulose. The method for preparing the aviation fuel intermediate has the following steps: using lignocellulose-derived aldehyde platform chemicals and lignocellulos...
|
|
WO/2020/259078A1 |
Provided is a method for preparing an adamantyl-containing triphenylamine derivative, the method comprising first reacting an aryl halogenated adamantane or an aryl adamantane ester with a primary aromatic amine without separation or pur...
|
|
WO/2020/257940A1 |
The present application provides furosemide analogues of the general formula Z having activity as anti-Aβ aggregation agents and/or as inhibitors of Aβ induced neuroinflammation. Formula Z These compounds are useful in preventing, dela...
|
|
WO/2020/258463A1 |
The high-efficiency pretreatment separation of hemicellulose from a fiber-based biomass raw material and a comprehensive utilization method therefor. Using a fiber-based biomass raw material which is a type of forest biomass resource as ...
|
|
WO/2020/262648A1 |
The present invention provides a compound that has an excellent pest-controlling effect and that is represented by formula (I) [in the formula, L represents an oxygen atom or CH2, E represents a C2-C10 chain hydrocarbon group or the like...
|
|
WO/2020/263660A1 |
The present invention provides processes for the preparation of 2-fluoroadenine, as well as certain intermediates useful in the preparation of 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine (EFdA): EFdA.
|
|
WO/2020/262451A1 |
The invention addresses the problem that metal-organic frameworks have conventionally only been produced with terephthalic acids having a limited range of substituents even though the amount and type of gas stored thereby can vary depend...
|
|
WO/2020/260058A1 |
The invention relates to a process for synthesizing a mixture of 5-hydroxymethylfurfural and glucose from a fructose-containing feedstock in the presence of at least one aprotic polar solvent and at least one dehydration catalyst, in whi...
|
|
WO/2020/264176A1 |
Heteroaryl and aliphatic analogs of diarylurea-based cannabinoid 1 receptor (CB1 R) allosteric modulators of formula (I) are described. Exemplary analogs can provide improved potencies and pharmacokinetic properties. Methods of using the...
|
|
WO/2020/260172A1 |
The invention relates to a process for converting furfural compounds to a reduced compound using a heterogeneous sulfide catalyst.
|
|
WO/2020/258408A1 |
Disclosed are a method for the efficient hydro-conversion of furfuryl alcohol, and a high-dispersion supported Pt catalyst, belonging to the field of biomass catalytic conversion. The use of the high-dispersion supported Pt catalyst belo...
|
|
WO/2020/262507A1 |
Provided are a compound that further improves the performance of an organic EL element, an organic electroluminescence element having improved element performance, and an electronic device including such an organic electroluminescence el...
|
|
WO/2020/253445A1 |
Provided are an organic electroluminescent material and an organic luminescent device comprising the organic electroluminescent material. The organic electroluminescent material has the structural formula of (I). Compared with a monoamin...
|
